Department of Dermatology, Center for Dermatooncology, University Hospital Tübingen, 72076 Tübingen, Germany.
Biomed Res Int. 2013;2013:102698. doi: 10.1155/2013/102698. Epub 2012 Dec 27.
The therapy for actinic keratoses includes photodynamic therapy (PDT) and imiquimod 5% cream. The sequential use of both could result in better clinical outcomes.
To enhance efficacy of therapies while improving tolerability, convenience, and patient adherence with a scheme combining two concomitant or sequential AK treatments.
All patients underwent one session of conventional PDT. Two weeks after, the PDT imiquimod 5% cream was applied to the treatment area once daily for three days per week. One course continued for four weeks followed by a clinical evaluation and decision about further treatment. Patients who had not cleared all of their AK lesions in the treatment area in course 1 participated in a second 4-week course of treatment. Limitations. Small size of population.
Three participants were enrolled. Two patients showed complete clinical clearance of AKs. The effect was also noted after long-term followup, at months seven and eleven. No subject discontinued for an adverse event. There were severe local skin reactions in two participants which were severe erythema, scaling, and crusting. One patient showed no response to the therapy.
Photodynamic therapy followed by imiquimod was well tolerated and improved reduction of actinic keratoses. This initial proof-of-concept should be studied in larger clinical trials.
光动力疗法(PDT)和咪喹莫特 5%乳膏均可用于治疗光化性角化病。这两种疗法序贯使用可能会获得更好的临床效果。
为了提高疗效,同时提高治疗的耐受性、便利性和患者的依从性,我们设计了一种方案,同时或序贯使用两种 AK 治疗药物。
所有患者均接受一次常规 PDT 治疗。2 周后,在治疗区域涂抹 PDT 咪喹莫特 5%乳膏,每周 3 天,每天 1 次。一个疗程持续 4 周,然后进行临床评估,并决定是否进行进一步治疗。在第 1 个疗程中,未清除治疗区域内所有 AK 病变的患者,参加第 2 个 4 周疗程的治疗。局限性:人口规模较小。
共纳入 3 名参与者。2 名患者的 AK 完全清除。在 7 个月和 11 个月的长期随访中也观察到了效果。没有患者因不良反应而停药。2 名参与者出现严重的局部皮肤反应,表现为严重的红斑、脱屑和结痂。1 名患者对治疗无反应。
PDT 后序贯使用咪喹莫特可耐受良好,能更好地减少光化性角化病。这一初步的概念验证应该在更大的临床试验中进行研究。